GRM2 and schizophrenia: Because the NMDA hypothesis provides a compelling explanation of the full range of symptoms in schizophrenia, several compounds have been explored as potential therapeutic agents for schizophrenia, including the glycine transporter 1 (GlyT1) inhibitor and mGlu2/3 receptor agonist, both of which are believed to modulate NMDA receptor function [15,16].